Guizhou Liangji Pharmaceutical Co, a modern high-tech enterprise specializing in Miao ethnic herbal medicines, has become a prime example of accelerating development in the Guizhou Shuanglong Airport Economic Zone.
An aerial view of Guizhou Liangji Pharmaceutical Co. [Photo/Guiyang news network]
From January to May this year, the company achieved an output value of 145.16 million yuan ($20.71 million), a year-on-year increase of 44.5 percent, with revenue reaching 117.28 million yuan.
According to Fu Zhengyou, the company's deputy general manager, its remarkable growth has been driven primarily by strategic e-commerce expansion. This move has significantly broadened the company's market reach, resulting in a substantial increase in orders and enabling continuous production.
Equipped with 43 drug approval certificates, eight exclusive products, and 10 good manufacturing practice production lines, the company has steadily strengthened its innovation capacity, increasing its R&D investment from 7.48 million yuan in 2022 to over 8 million yuan in 2024.
Supported by favorable policies, resources, and talent in the zone, the company is currently in its first expansion phase, with plans to upgrade its storage, preparation, and extraction facilities in the second phase.
The company's annual output value is projected to rise to between 1 and 1.5 billion yuan over the next five years, creating approximately 100 new jobs and boosting local herb cultivation and related industries.
The company exemplifies Shuanglong zone's thriving pharmaceutical ecosystem, which now hosts 398 medical enterprises, including 22 manufacturers and 376 sales companies, nine of which exceed the designated size. From January to May this year, these nine enterprises recorded industrial output exceeding 600 million yuan.